What are the most common side effects associated with jaypirca when used for treating relapsed refractory mantle cell lymphoma?

Jaypirca ( pirtobrutinib ) is a BTK inhibitor used for relapsed or refractory mantle cell lymphoma after prior therapies. The most common side effects reported for Jaypirca include:

• Low blood counts (cytopenias), such as:
  • Neutropenia
  • Anemia
  • Thrombocytopenia
• Fatigue
• Diarrhea
• Rash
• Nausea
• Musculoskeletal pain (e.g., arthralgia or pain in limbs/joints)
• Upper respiratory infections / cough (and other infections)

Some patients may also experience infections overall, and bleeding/bruising can occur with BTK inhibitors (though pirtobrutinib is often associated with a lower rate of bleeding than some other agents).

If you want, tell me which clinical context you’re asking about (e.g., specific trial or line of therapy), and I can tailor the list to the most relevant study population.